Virginie Julien

• Advising Virbac, a French pharmaceutical laboratory dedicated to animal health, on the acquisition from Norbrook of an innovative drug to stabilize feline hyperthyroidism.
• Advising Pierre Fabre on the sale of the Centre Immunologie Pierre Fabre, located in Saint-Julien-en-Genevois, together with the research and development activities carried out at the site, to Jubilant Group, an international Indian pharmaceutical group seeking to expand its CRO activities in Europe through the acquisition of a pharmaceutical site.
• Advising UMPC (US) in connection with its participation in various rounds of financing for GenSight Biologics, a French biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.
• Advising Halma, the global group of life-saving technology companies, on the cross-border acquisition of 100% of the shares and voting rights in French-based Lamidey Noury Medical, reinforcing its international footprint between France and England & Wales.
• Advising Stryker, a US medical technology company, in the context of the acquisition of Serf SAS, a medical device manufacturer/seller that is a wholly owned subsidiary of a French company, located near Lyon France.
• Advising Pierre Fabre on the acquisition of Vertical Bio, a Basel-based drug discovery and development company incubated by Ridgeline Discovery (Versant Ventures).
• Advising Resmed in its investment in Biosency, a French medtech company. 
• Advising Emergent Biotechnologies on its acquisition of a joint venture interest and product portfolio from Sanofi.
• Advising Renault group on a number of transactions, including the sale of its distribution business in Romania, the sale of its distribution business in Ireland and its program to divest its automotive distribution business in Central and Eastern Europe and Northern Europe.
• Advising Chemonics International, Inc., a global sustainable development firm, on its acquisition of D.M.I, a French international development company. 
• Advising Proparco on its acquisition of a stake in Finafrica.
• Advising Société Générale group on a number of transactions, including (i) ALD Automotive’s joint-venture with Bangkok Mitsubishi HC Capital Co., Ltd and Mitsubishi HC Capital Inc, establishing a multi-brand, full service operational leasing and fleet management business for corporate clients in Thailand, (ii) its participation in a Cap Gemini/Credit Agricole joint-venture named “Azqore” and (iii) its acquisition of Shine, a French fintech and neobank.
• Advising BIC on its acquisition of Advanced Magnetic Interaction (AMI), a French start-up specializing in augmented interaction technology.
• Advising Sodexo in connection with the sale of its global homecare division to Halifax group.

Team recognitions

• Chambers France 2025 – Pharma/Life Sciences – Band 4
  “The team have deep knowledge of our industry and a strong track record.”
  “I like the firm's knowledge of the market and our company, their availability and their responsiveness.”
  “The firm answers my needs in terms of cross-practice skills, values and empathy. The lawyers listen to the clients and they are available.”
  “I am satisfied with their interpersonal skills with the client and their ability to be a real business partner.”
• Legal 500 EMEA 2025 - Industry Focus: Healthcare and Life Sciences - Tier 2
  “International firm with extensive expertise. Interest in complex cases requiring varied and highly specialised resources and expertise.”
  “Skills in the health sector and diversity in areas of expertise (litigation, administrative, regulatory).”
  “The team is very cohesive and diligent in implementation. It is very experienced in acquisitions, divestments and industrial contracts in the field of pharmaceuticals and medical devices. It has good international experience and benefits from a competent network in the field, particularly in the US.”
• Legal 500 EMEA 2025 - Private Equity: LBO - Tier 3 –
  "Availability, in-depth expertise, ability to support both SMEs and large international groups.”
  
• Legal 500 EMEA 2025- Mergers & acquisitions - Tier 4
  "Great organisational capabilities combined with a focused professional approach and excellent connections worldwide.”
  
• Option Droit & Affaires – Mergers & acquisitions – 5 stars – 2025
• Option Droit & Affaires – Private Equity – 5 stars - 2025